Zevra Therapeutics (ZVRA) Other Working Capital Changes (2014 - 2026)
Zevra Therapeutics (ZVRA) reported Other Working Capital Changes of $416000.0 for Q1 2026, up 318.95% on a YoY basis from $99296.5 in Q1 2025, and up 422.48% quarter-over-quarter from -$129000.0 in Q4 2025.
Zevra Therapeutics (ZVRA) Other Working Capital Changes (2014 - 2026) Analysis & Trends
Zevra Therapeutics has reported Other Working Capital Changes for 13 years, with the latest figure at $416000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Working Capital Changes rose 318.95% year-over-year to $416000.0; the trailing twelve-month figure through Mar 2026 stood at -$69000.0 (up 86.68% YoY), and the FY2025 full-year result was -$675000.0, down 183.38% from the prior year.
- Other Working Capital Changes for Q1 2026 stood at $416000.0, up from -$129000.0 in the prior quarter.
- The five-year high for Other Working Capital Changes was $2.2 million in Q2 2022, with the low at -$1.1 million in Q4 2024.
- Historically, Other Working Capital Changes has averaged -$8411.8 across 5 years, with a median of -$190000.0 in 2025.
- Annual changes were most pronounced in 2024 — Other Working Capital Changes sank 762.4% — and 2026, when it surged 318.95%.
- Zevra Therapeutics' Other Working Capital Changes stood at -$302000.0 in 2022, then soared by 58.61% to -$125000.0 in 2023, then tumbled by 762.4% to -$1.1 million in 2024, then surged by 88.03% to -$129000.0 in 2025, then soared by 422.48% to $416000.0 in 2026.
- The last three Other Working Capital Changes figures came in at $416000.0 (Q1 2026), -$129000.0 (Q4 2025), and -$842000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Zevra Therapeutics | 796.95 Mn | 596.33 Mn | 34.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 416,000.00 |
| Mar 31, 2026 | 416,000.00 |
| Dec 31, 2025 | -129,000.00 |
| Dec 31, 2025 | -129,000.00 |
| Sep 30, 2025 | -842,000.00 |
| Sep 30, 2025 | -842,000.00 |
| Jun 30, 2025 | 486,000.00 |
| Jun 30, 2025 | 486,000.00 |
| Mar 31, 2025 | -190,000.00 |
| Mar 31, 2025 | -190,000.00 |
| Dec 31, 2024 | -1.08 Mn |
| Dec 31, 2024 | -1.08 Mn |
| Sep 30, 2024 | -410,000.00 |
| Sep 30, 2024 | -410,000.00 |
| Jun 30, 2024 | 1.16 Mn |
| Jun 30, 2024 | 1.16 Mn |
| Mar 31, 2024 | -298,000.00 |
| Mar 31, 2024 | -298,000.00 |
| Dec 31, 2023 | -125,000.00 |
| Dec 31, 2023 | -125,000.00 |